PEG-MGF
GH SecretagoguesPegylated Mechano Growth Factor — Synthetic Peptide
Overview
PEG-MGF (pegylated mechano growth factor) is the PEGylated form of the MGF E-domain peptide (see MGF entry). PEGylation — attachment of polyethylene glycol chains to the peptide — is a pharmaceutical strategy to reduce renal clearance and proteolytic degradation, extending the plasma half-life of short peptides from minutes to hours or days.
**Evidence status:** No peer-reviewed PubMed-indexed studies for "PEG-MGF" as a named compound have been published. All evidence for PEG-MGF must be extrapolated from: 1. The parent MGF E-domain peptide pharmacology (see MGF entry) 2. General PEGylated peptide pharmacokinetic principles
The molecular weight varies with PEG chain length; commercially sold PEG-MGF typically adds 1–5 kDa PEG to the ~2.87 kDa MGF E-domain, resulting in a compound of approximately 4–8 kDa. Molecular weight and formula fields cannot be precisely specified and are listed as not applicable.
Mechanism of Action
PEG-MGF is mechanistically identical to unmodified MGF E-domain at the receptor level: the E-domain peptide retains its satellite cell-activating activity via the non-IGF-1R receptor. PEGylation adds pharmacokinetic modification: - **Extended half-life:** Reduces renal filtration (PEG chains increase hydrodynamic radius above glomerular filtration cutoff) and slows proteolytic access to the peptide backbone - **Systemic vs. local action:** Unmodified MGF acts locally at the site of mechanical stress; PEG-MGF's extended half-life enables systemic circulation and potentially broader tissue distribution - **Reduced receptor affinity trade-off:** PEGylation commonly reduces receptor binding affinity due to steric hindrance from the PEG chains — an empirically documented pharmacodynamic trade-off for pegylated peptides and proteins
Whether the extended half-life benefit outweighs the reduced receptor affinity in the context of satellite cell activation has not been investigated in any published study.
Research Dosing
PEG-MGF is sold by research peptide vendors but has no peer-reviewed pharmacokinetic or clinical data. The PEGylation is intended to extend the native MGF E-domain half-life from ~5–10 minutes to hours or days, but the actual half-life of commercially sold PEG-MGF formulations has not been independently characterized. No human clinical trials exist. WADA-monitored.
Research data only. These dosing ranges are derived from published studies, primarily in animal models. This is not medical advice. No peptide discussed on this site is approved for human therapeutic use unless otherwise noted.